{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Zymeworks Inc."},"Symbol":{"label":"Symbol","value":"ZYME"},"Address":{"label":"Address","value":"1385 WEST 8TH AVENUE,SUITE 540 SUITE A, VANCOUVER, British Columbia, V6H 3V9, Canada"},"Phone":{"label":"Phone","value":"+1 604 678-1388"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas."},"CompanyUrl":{"label":"Company Url","value":"https://www.zymeworks.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Barbara Schaeffler","title":"Vice President-Clinical Development Opeartions"},{"name":"Jeffrey T. L. Smith","title":"Chief Medical Officer & Executive Vice President"},{"name":"Kenneth Harry Galbraith","title":"Chairman, President, Chief Executive Officer & CFO"},{"name":"Mark Hollywood","title":"EVP, Head-Technical & Manufacturing Operations"},{"name":"Paul A. Moore","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}